Affiliation:
1. Department of Radiology Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing Jiangsu 210029 P. R. China
2. Marshall Laboratory of Biomedical Engineering International Cancer Center Laboratory of Evolutionary Theranostics (LET) School of Biomedical Engineering Shenzhen University Health Science Center Shenzhen Guangdong 518060 P. R. China
3. Department of Medical Imaging Jinling Hospital School of Medicine Nanjing University Nanjing Jiangsu 210002 P. R. China
Abstract
AbstractAlthough photothermal therapy (PTT) can noninvasively kill tumor cells and exert synergistic immunological effects, the immune responses are usually harmed due to the lack of cytotoxic T cells (CTLs) pre‐infiltration and co‐existing of intricate immunosuppressive tumor microenvironment (TME), including the programmed cell death ligand 1 (PD‐L1)/cluster of differentiation 47 (CD47)/regulatory T cells (Tregs)/M2‐macrophages overexpression. Indoleamine 2, 3‐dioxygenase inhibitor (NLG919) or bromodomain extra‐terminal inhibitor (OTX015) holds great promise to reprogram suppressive TME through different pathways, but their collaborative application remains a formidable challenge because of the poor water solubility and low tumor targeting. To address this challenge, a desirable nanomodulator based on dual immune inhibitors loaded mesoporous polydopamine nanoparticles is designed. This nanomodulator exhibits excellent biocompatibility and water solubility, PTT, and bimodal magnetic resonance/photoacoustic imaging abilities. Owing to enhanced permeability and retention effect and tumor acidic pH‐responsiveness, both inhibitors are precisely delivered and locally released at tumor sites. Such a nanomodulator significantly reverses the immune suppression of PD‐L1/CD47/Tregs, promotes the activation of CTLs, regulates M2‐macrophages polarization, and further boosts combined therapeutic efficacy, inducing a strong immunological memory. Taken together, the nanomodulator provides a practical approach for combinational photothermal‐immunotherapy, which may be further broadened to other “immune cold” tumors.
Funder
National Natural Science Foundation of China
Subject
Biomaterials,Biotechnology,General Materials Science,General Chemistry
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献